Section Review: Oncologic, Endocrine & Metabolic: Future directions for the treatment of human pancreatic carcinoma

References

• GORDIS L: Epidemiology of pancreatic cancer. World J. Surg. (1984) 8:808–821.
   PubMed Web of Science ®Google Scholar
• NATIONAL CANCER INSTITUTE: Annual cancer statistics review 1973–1988. MH Publication No. 91–2789. Dept. of Health and Human Services. Bethesda (1991).
   Google Scholar
• BORING CC, SQUIRES TS, TONG T: Cancer statistics, 1991.CA (1991) 41:19–36.
   Google Scholar
• LELLEMOE KD: Pancreatic disease in the elderly patient.Surgery in the Elderly Patient .II (1994) 74:317–344.
   Google Scholar
• GIRELLI CM, REGUZZONI G, BARZAGHI F, BERRINO F:Changes in diagnostic approach and factors affecting treatment and survival of pancreatic carcinoma in a retrospective series over twelve years. Tumori (1994) 80:198–203.
   PubMed Web of Science ®Google Scholar
• CUBILLA AL, FITZGERALD PJ: Cancer of the pancreas(non-endocrine): A suggested morphologic clarifica-tion. Semin. Oncol. (1979)6:285.
   PubMed Web of Science ®Google Scholar
• DIAMOND D, FISHER B: Pancreatic cancer. Surg. Ctn.North Am. (1975) 55:363–376.
   PubMed Web of Science ®Google Scholar
• GUDJONSSON B: Cancer of the pancreas: 50 years ofsurgery. Cancer (1987) 9:2284–2303.
   Google Scholar
• WHIPPLE A, PARSONS W, MULLINS C: Treatment of car-cinoma of the ampulla of Vater. Ann. Surg. (1935) 102:763–779.
   PubMedGoogle Scholar
• WATANAPA P, WILLIAMSON RCN: Surgical palliation for pancreatic cancer: Developments during the past two decades. Br. J. Surg. (1992) 79:8–20.
   PubMed Web of Science ®Google Scholar
• BRENNAN MF, KINSELLA TJ, CASPER ES: Cancer of the pancreas. In: Cancer: Principles and Practice of Oncology (Fourth Edition). DeVita VT, Hellman S, Rosenberg SA (Eds). JB Lippincott Co., Philadelphia (1993):849–882.
   Google Scholar
• A good overview of human pancreatic carcinoma and its treatment.
   Google Scholar
• SCHULTZ RM: Biology and chemotherapeutic manage-ment of pancreatic carcinoma. Drugs of Today (1994) 30:483–496.
   Google Scholar
• ARBUCK SG: Overview of chemotherapy for pancreatic cancer. Intl. PancreatoL (1990) 7:209–222.
   PubMedGoogle Scholar
• O'CONNELL MJ: Current status of chemotherapy for advanced pancreatic and gastric cancer. J Gun. Chico!. (1985) 3:1032–1039.
   Google Scholar
• WILS JA: Current status of chemotherapy in metastatic pancreatic cancer. Anticancer Res. (1989) 9:2027–1032.
   Google Scholar
• KOVACH JS, MOERTEL CG, SCHUTT AJ, ETAL.: A control-led study of combined 1,3-bis-(2-chlorethyl)-1-ni-trosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer (1974) 33:563.
   Google Scholar
• CULLINAN SA, MOERTEL CG, FLEMING TR, ET AL.: A comparison of chemotherapeutic regimens in the treat-ment of advanced pancreatic and gastric carcinoma. JAMA (1985) 253:2061–2067.
   Google Scholar
• CULLINAN SA, MOERTEL CG, WIEAND HS, ETAL.: A Phase M trial on the therapy of advanced pancreatic carci-noma: Cancer (1990) 65:2207–2212.
   Google Scholar
• LIONET'TO R, PUGLLESE V, BRUZZI P, ROSSO R: No stand- ard treatment is available for advanced pancreatic can-cer. Eur. J. Cancer (1995) 31A:882–887.
   PubMed Web of Science ®Google Scholar
• Review of randomised chemotherapy trials published from 1980-1993.
   Google Scholar
• CANCER OF THE PANCREAS TASK FORCE: Staging of cancer of the pancreas. Cancer (1981) 47:1631.
   PubMed Web of Science ®Google Scholar
• CASPER ES: Pancreatic cancer: how can we progress? Eur.J. Cancer (1993) 29A:171–172.
   Web of Science ®Google Scholar
• STEINBERG W: The clinical utility of the CA 19-9 tumor-sociated antigen. Am.J.Gastroenterol. (1990) 85:350–355.
   PubMed Web of Science ®Google Scholar
• MAHVI DM, MEYERS WC, BAST RC, ETAL.: Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody in carcinoma of the pancreas. Ann. Surg. (1985) 202:440.
   Google Scholar
• GOLD DV, LEW K, MALINIAK R, HERNANDEZ M, CARDILLOT: Characterization of monoclonal antibody PAM4 re-active with a pancreatic cancer MUCill. Int. J. Cancer (1994) 57:204–210.
   PubMed Web of Science ®Google Scholar
• KIRIYAMA S, HAYAKAWA T, KONDO T, ETAL.: Usefulness of a new tumor marker, SPAN-1, for the diagnosis of pancreatic cancer. Cancer (1990) 65:1557–1561.
   Google Scholar
• NGHIEM Ely, FREENY PC: Radiologic staging of pancre-atic adenocarcinoma. Radiol. din. North Am. (1994) 32:71–79.
   PubMed Web of Science ®Google Scholar
• GRAHAM RA, BANKOFF M, HEDIGER R, SHAKER HZ, REINHOLD RB: Fine-needle aspiration biopsy of pancre-atic ductal adenocarcinoma: loss of diagnostic accuracy with small tumors. J. Surg. Oncol. (1994) 55:92–94.
   PubMed Web of Science ®Google Scholar
• TSUCHIGA R, NODA T, HARADA N, ET AL.: Collective review of small carcinomas of the pancreas. Ann. Surg. (1986) 203:77–84.
   Google Scholar
• CHANG KJ, ALBERS CG, ERICKSON RA, BUTLER JA, WUERKER RB, LIN FL: Endoscopic ultrasound-guided fine needle aspiration of pancreatic carcinoma. Am. J. Gastruenterol. (1994) 89:263–266.
   PubMed Web of Science ®Google Scholar
• VOGELSTEIN B, KINZLER KW: The multistep nature ofcancer. Trends Genet. (1993) 9:138–141.
   PubMed Web of Science ®Google Scholar
• BOS JL: Ras oncogenes in human cancer: A review. Cancer Res. (1989) 49:4682–4689.
   PubMed Web of Science ®Google Scholar
• A thorough review of ras oncogenes in human cancer.
   Google Scholar
• TRAHEY M, MCCORMICK F: A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science (1987) 238:542–545.
   PubMed Web of Science ®Google Scholar
• ALMOGUERA C, SHIBATA D, FORRESTER K, ETAL.: Most human carcinomas of the exocrine pancreas contain c-K-ras genes. Cell (1988) 53:549–554.
   Google Scholar
• TADA M, OMATA M, OHTO M: Clinical application of ras gene mutation for diagnosis of pancreatic adenocarci-noma. Gastroenterol. (1991) 100:233–238.
   PubMed Web of Science ®Google Scholar
• SMITS VTHBM, BOOT AJM, SMITS AMM, ET AL.: K-rascodon 12 mutations occur very frequently in pancreatic adeno-carcinomas. Nucleic Acids Res. (1988) 16:7773–7782.
   Google Scholar
• VOGELSTEIN B, KINZLER KW: Carcinogens leave foot-prints. Nature (1992) 355:209–210.
   PubMed Web of Science ®Google Scholar
• URBAN T, RICCI S, GRANGE J-D, ETAL.: Detection ofc-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J. Natl. Cancer Inst. (1993) 85:2008–1012.
   Google Scholar
• SORENSON GD, PRIBLISH DM, VALONE FH, ETAL.: Solublenormal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol. Biomarkers Prevention (1994) 3:67–71.
   Google Scholar
• KONDO H, SUGANO K, FUKAYAMA N, ETAL.: Detectionof point mutations in the k-ras oncogene at codon 12 In pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer (1994) 73:1589–1594.
   Google Scholar
• CALDAS C, HAHN SA, HRUBAN RH, ETAL.: Detection ofk-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. (1994) 54:3568–3573.
   Google Scholar
• QUAIFE CJ, PINICERT CA, ORNITZ DM, ETAL.: Pancreaticneoplasia induced by ras expression in acinar cells of transgenic mice. Cell (1987) 48:1023–1034.
   Google Scholar
• URA H, OBARA T, NISHINO N, ET AL.: Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells con-taining mutant ras gene. Jpn. J. Cancer Res. (1994) 85:633–638.
   Google Scholar
• BARTON CM, STADDON SL, HUGHES CM, ET AL.: Abnor-malities of the tumor suppressor gene p53 in human pancreatic cancer. Br. J. Cancer (1991) 64:1076–1082.
   Google Scholar
• RUGGERI B, ZHANG S-Y, CAAMANO J, ET AL.: Human pancreatic carcinoma and cell lines reveal frequent and multiple alterations in the p53 and RB-1 tumor-suppres-sor genes. Oncogene (1992) 7:1503–1511.
   Google Scholar
• SIMON B, WEINEL R, HOHNE M, ET AL.: Frequent altera-tions of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma. Gastroenterol. (1994) 106:1645–1651.
   Google Scholar
• HALL PA, LEMOINE NR: Models of pancreatic cancer. Cancer Surv. (1993) 16:135–155.
   PubMedGoogle Scholar
• Review of in vitro and in vivo model systems for pancreatic cancer.
   Google Scholar
• WYLLIE FS, LEMOINE NR, BARTON CM, ET AL.: Direct growth stimulation of normal human epithelial cells by mutant p53. Mol. Carcinogenesis (1993) 7:83–88.
   Google Scholar
• HINDS P, FINLAY C, LEVINE AL Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol. (1989) 63:739–746.
   PubMed Web of Science ®Google Scholar
• LEMOINE NR, HUGHES CM, BARTON CM, ET AL.: The epidermal growth factor receptor in human pancreatic cancer. J. Pathol. (1992) 166:7–12.
   Google Scholar
• BARTON CM, HALL PA, HUGHES CM, ET AL.: Transform-ing growth factor alpha and epidermal growth factor Inhuman pancreatic cancer. J. Pathol. (1991) 163:111–116.
   Google Scholar
• JIE C, TONG-HUA L: Expression of EGF, TGFot, EGFR and c-erbB2 genes and their gene products in human pan-creatic carcinoma cell lines. Zentralbl. Pathol. (1994) 140:265–270.
   PubMedGoogle Scholar
• ROSENTHAL A, LUNDQUIST PB, BRINGMAN TS, ET AL.: Expression in rat fibroblasts of a human transforming growth factor-alpha cDNA results in transformation. Cell (1986) 46:301–309.
   Google Scholar
• CHEN YF, PAN G-Z, HOU X, ET AL.: Epidermal growth factor and its receptor in human pancreatic carcinoma. Pancreas (1990) 5:278–283.
   Google Scholar
• SMITH JJ, DERYNCK R, KORC M: Production of transform-ing growth factor-alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc. Natl. Acad. Sci. USA d(1987) 84:7567–7570.
   PubMed Web of Science ®Google Scholar
• CHESTER JF, GAISSERT HA, ROSS JS, MALT RA: Pancreatic cancer in the Syrian hamster induced by N-nitrosobis-(2-oxypropyHamine: cocarcinogenic effect of epider-mal growth factor. Cancer Res. (1986) 46:2954–2957.
   PubMed Web of Science ®Google Scholar
• WILLIAMS JA, GOLDFINE ID: The insulin-acinar relation-ship. In: The Exocrine Pancreas. Go VLM, Gardner JD, Brooks FP, Lebenthal E, DiMagno EP, Scheele GA (Eds.). Raven Press, New York (1986):347–360.
   Google Scholar
• FROSCH RG, BUSBY WH, SCHWANDER J: Actions of Insulin-like growth factors. Ann. Rev. Physiol. (1985) 47:443–467.
   PubMed Web of Science ®Google Scholar
• BASERGA R: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. (1995) 55:249–252.
   Google Scholar
• OHMURA E, LKADA M, ONODA N, ET AL.: Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res. (1990) 50:103–107.
   Google Scholar
• BERGMANN U, FUNATOMI H, YOKOYAMA M, BEGER HG, KORC M: Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. (1995) 55:2007–2011.
   PubMed Web of Science ®Google Scholar
• Klapdor R: Perspectives in chemotherapy of pancreatic cancer. Eur. J. Sur. Oncol. (1991) 17:153–166.
   PubMed Web of Science ®Google Scholar
• VANCUTSEM E, FEVERY J: Pancreatic cancer: a plea for more trials. Eur. J. Cancer (1995) 31A:867–869.
   PubMed Web of Science ®Google Scholar
• HERTEL LW, BODER GB, ICROIN JS, RINZEL SM, POORE GA, TODD GC, GRINDEY GB: Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytid-ine). Cancer Res. (1990) 50:4417–4422.
   PubMed Web of Science ®Google Scholar
• CASPER ES, GREEN MR, KELSEN DP, ET AL.: Phase II trialof gemcitabine (2',2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs (1994) 12:29–34.
   Google Scholar
• ROTHENBERG ML, BURRIS HA, ANDERSEN JS, ET AL.: Gemcitabine: effective palliative therapy for pancreascancer patients failing 5-FU. Proc. ASCO (1995) 14:470a. Gemcitabine produces palliation of symptoms in pancreatic carci-noma patients.
   Google Scholar
• MOORE M, ANDERSEN J, BURRIS H, ET AL.: A randomized trial of gemcitabine versus 5FU as first-line therapy in advanced pancreatic can. Proc. Amer. Soc. Clin. Oncol. (1995) 14:473a.
   Google Scholar
• HOFFMAN JP, WEESE JL, SOLIN LJ, ET AL.: A single insti-tutional experience with preoperative chemora-diotherapy for stage I-M pancreatic adenocarcinoma. Amer. Surg. (1993) 59:772–781.
   Google Scholar
• WEESE JL, NUSSBAUM ML, PAUL AR, ET AL.: Increased resectability of locally advanced pancreatic and periam-pullary carcinoma with neoadjuvant chemora-diotherapy. Int. J. Pancreatol. (1990) 7:177–185.
   Google Scholar
• BRUCKNER HW, KALNICKI S, DALTON J., ET AL.: Com-bined modality therapy increasing local control on pancreatic cancer. Cancer Invest. (1993) 11: 241–246.
   Google Scholar
• ISOCOFF WH, REBER H, TOMPKINS R, ET AL.: Continuous Infusion (CI) 5-fluorouracil (5-FU), calcium leucovorin (LV), mitomycin-C (mito C), and dipyridatnole (D) treat-ment for patients with locally advanced pancreatic cancer. Proc. ASCO (1995) 14:471a.
   Google Scholar